Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: A report from the children's oncology group

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 6, 2008, Pages 1027-1037

  Thompson, Patrick A ^a   Gupta, Manish ^b   Rosner, Gary L ^c   Yu, Alexander ^a   Barrett, Jeffrey ^b   Bomgaars, Lisa ^a   Bernstein, Mark L ^d   Blaney, Susan M ^a   Mondick, John ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d IWK HEALTH CENTRE   (Canada)

Author keywords

CPT 11; Irinotecan; Pediatrics; Pharmacokinetics; Population modeling

Indexed keywords

7 ETHYL 10 [4 N (5 AMINOPENTANOIC ACID) 1 PIPERIDINO]CARBONYLOXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; DRUG METABOLITE; IRINOTECAN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; COMPARTMENT MODEL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REDUCTION; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MULTICENTER STUDY; PARAMETER; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL; SOLID TUMOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BILIRUBIN; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A; FEMALE; GLUCURONATES; GLUCURONOSYLTRANSFERASE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MULTICENTER STUDIES AS TOPIC; NEOPLASMS;

EID: 51849118469     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0692-z     Document Type: Article

References (49)

1. Y Ando Y Hasegawa 2005 Clinical pharmacogenetics of irinotecan (CPT-11) Drug Metab Rev 37 565 574
2. Y Ando H Ueoka T Sugiyama M Ichiki K Shimokata Y Hasegawa 2002 Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan Ther Drug Monit 24 111 116
3. S Blaney SL Berg C Pratt S Weitman J Sullivan L Luchtman-Jones M Bernstein 2001 A phase I study of irinotecan in pediatric patients: a pediatric oncology group study Clin Cancer Res 7 32 37
4. L Bomgaars M Bernstein M Krailo R Kadota S Das Z Chen P Adamson S Blaney 2007 Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study J Clin Oncol 25 4622 4627
5. L Bomgaars J Kerr S Berg J Kuttesch R Klenke SM Blaney 2006 A phase I study of irinotecan administered on a weekly schedule in pediatric patients Pediatr Blood Cancer 46 50 55
6. GG Chabot 1997 Clinical pharmacokinetics of irinotecan Clin Pharmacokinet 33 245 259
7. FA de Jong MJ de Jonge J Verweij RH Mathijssen 2006 Role of pharmacogenetics in irinotecan therapy Cancer Lett 234 90 106
8. FA de Jong JJ Kitzen P de Bruijn J Verweij WJ Loos 2006 Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain Cancer Biol Ther 5 1105 1110
9. BM Frost S Eksborg O Bjork J Abrahamsson M Behrendtz A Castor E Forestier G Lonnerholm 2002 Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study Med Pediatr Oncol 38 329 337
10. WL Furman KR Crews C Billups J Wu AJ Gajjar NC Daw CC Patrick C Rodriguez-Galindo CF Stewart JS Dome JC Panetta PJ Houghton VM Santana 2006 Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors J Clin Oncol 24 563 570
11. WL Furman CF Stewart CA Poquette CB Pratt VM Santana WC Zamboni LC Bowman MK Ma FA Hoffer WH Meyer AS Pappo AW Walter PJ Houghton 1999 Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children J Clin Oncol 17 1815 1824
12. Gastonguay M, El-Tahtawy A (2005) Modeling and simulation guided design of a pediatric population pharmacokinetic trial for hydromorphone. AAPS Journal 7: Abstract W5318
13. JY Han HS Lim ES Shin YK Yoo YH Park JE Lee IJ Jang DH Lee JS Lee 2006 Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin J Clin Oncol 24 2237 2244
14. F Innocenti MJ Ratain 2004 "Irinogenetics" and UGT1A: from genotypes to haplotypes Clin Pharmacol Ther 75 495 500
15. F Innocenti SD Undevia L Iyer PX Chen S Das M Kocherginsky T Karrison L Janisch J Ramirez CM Rudin EE Vokes MJ Ratain 2004 Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan J Clin Oncol 22 1382 1388
16. L Iyer L Janisch S Das J Ramirez CE Hurley-Buterman MM DeMario EE Vokes HL Kindler MJ Ratain 2000 UGT1A1 promoter genetype correlates with pharmacokinetics of irinotecan (CPT-11) Proc ASCO 19 178a
17. WJ Jansen GM Kolfschoten CA Erkelens J Van Ark-Otte HM Pinedo E Boven 1997 Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma Int J Cancer 73 891 896
18. M Karlsson R Savic 2007 Diagnosing model diagnostics Clin Pharmacol Ther 82 17 20
19. Y Kawato M Aonuma Y Hirota H Kuga K Sato 1991 Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 Cancer Res 51 4187 4191
20. GL Kearns SM Abdel-Rahman SW Alander DL Blowey JS Leeder RE Kauffman 2003 Developmental pharmacology-drug disposition, action, and therapy in infants and children N Engl J Med 349 1157 1167
21. TW Kim F Innocenti 2007 Insights, challenges, and future directions in irinogenetics Ther Drug Monit 29 265 270
22. CE Klein E Gupta JM Reid PJ Atherton JA Sloan HC Pitot MJ Ratain H Kastrissios 2002 Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide Clin Pharmacol Ther 72 638 647
23. MK Ma WC Zamboni KM Radomski WL Furman VM Santana PJ Houghton SK Hanna AK Smith CF Stewart 2000 Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan Clin Cancer Res 6 813 819
24. JW Mandema D Verotta LB Sheiner 1992 Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects J Pharmacokinet Biopharm 20 511 528
25. E Marcuello A Altes A Menoyo E Del Rio M Gomez-Pardo M Baiget 2004 UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer Br J Cancer 91 678 682
26. S Marsh 2005 Pharmacogenetics of colorectal cancer Expert Opin Pharmacother 6 2607 2616
27. S Marsh HL McLeod 2004 Pharmacogenetics of irinotecan toxicity Pharmacogenomics 5 835 843
28. RH Mathijssen S Marsh MO Karlsson R Xie SD Baker J Verweij A Sparreboom HL McLeod 2003 Irinotecan pathway genotype analysis to predict pharmacokinetics Clin Cancer Res 9 3246 3253
29. HL McLeod MV Relling WR Crom K Silverstein S Groom JH Rodman GK Rivera WM Crist WE Evans 1992 Disposition of antineoplastic agents in the very young child Br J Cancer Suppl 18 S23 S29
30. HL McLeod JW Watters 2004 Irinotecan pharmacogenetics: is it time to intervene? J Clin Oncol 22 1356 1359
31. R Mehra J Murren G Chung B Smith A Psyrri 2005 Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism Clin Colorectal Cancer 5 61 64
32. JA Meyerhardt A Kwok MJ Ratain JP McGovren CS Fuchs 2004 Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer J Clin Oncol 22 1439 1446
33. H Minderman S Cao YM Rustman 1998 Rational design of irinotecan administration based on preclinical models Oncology (Williston Park) 12 22 30
34. T Miya T Goya H Fujii T Ohtsu K Itoh T Igarashi H Minami Y Sasaki 2001 Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11 Invest New Drugs 19 61 67
35. H Mugishima T Matsunaga K Yagi K Asami J Mimaya S Suita T Kishimoto T Sawada Y Tsuchida M Kaneko 2002 Phase I study of irinotecan in pediatric patients with malignant solid tumors J Pediatr Hematol Oncol 24 94 100
36. L Paoluzzi AS Singh DK Price R Danesi RH Mathijssen J Verweij WD Figg A Sparreboom 2004 Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38 J Clin Pharmacol 44 854 860
37. MJ Ratain 2006 From bedside to bench to bedside to clinical practice: an odyssey with irinotecan Clin Cancer Res 12 1658 1660
38. K Sai M Saeki Y Saito S Ozawa N Katori H Jinno R Hasegawa N Kaniwa J Sawada K Komamura K Ueno S Kamakura M Kitakaze Y Kitamura N Kamatani H Minami A Ohtsu K Shirao T Yoshida N Saijo 2004 UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer Clin Pharmacol Ther 75 501 515
39. LJ Schaaf LA Hammond SJ Tipping RM Goldberg R Goel JG Kuhn LL Miller LD Compton LA Cisar GL Elfring G Gruia JP McGovren N Pirotta D Yin A Sharma BA Duncan ML Rothenberg 2006 Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction Clin Cancer Res 12 3782 3791
40. NF Smith WD Figg A Sparreboom 2006 Pharmacogenetics of irinotecan metabolism and transport: an update Toxicol In Vitro 20 163 175
41. CF Stewart 2001 Topoisomerase I interactive agents Cancer Chemother Biol Response Modif 19 85 128
42. CF Stewart JC Panetta MA O'Shaughnessy SL Throm CH Fraga T Owens T Liu C Billups C Rodriguez-Galindo A Gajjar WL Furman LM McGregor 2007 UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan J Clin Oncol 25 2594 2600
43. SL Traub L Kichen 1983 Estimating ideal body mass in children Am J Hosp Pharm 40 107 110
44. G Vassal D Couanet E Stockdale A Geoffray B Geoerger D Orbach F Pichon JC Gentet S Picton C Bergeron L Cisar S Assadourian B Morland 2007 Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group J Clin Oncol 25 356 361
45. G Vassal F Doz D Frappaz K Imadalou E Sicard A Santos J O'Quigley C Germa ML Risse D Mignard F Pein 2003 A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors J Clin Oncol 21 3844 3852
46. AP Venook C Enders Klein G Fleming D Hollis CG Leichman R Hohl J Byrd D Budman M Villalona J Marshall GL Rosner J Ramirez H Kastrissios MJ Ratain 2003 A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863 Ann Oncol 14 1783 1790
47. AJ Xiao J Fiedler-Kelly LJ Schaaf GL Elfring S Sardella M Redman 2002 Simultaneous population pharmacokinetic (PPK) modeling of irinotecan (CPT-11) and its major metabolites Clin Pharmacol Ther 71 P63
48. R Xie RH Mathijssen A Sparreboom J Verweij MO Karlsson 2002 Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea Clin Pharmacol Ther 72 265 275
49. R Xie RH Mathijssen A Sparreboom J Verweij MO Karlsson 2002 Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis J Clin Oncol 20 3293 3301